From the Guidelines
Recommended Dose of Augmentin for Community-Acquired Pneumonia
The recommended dose of Augmentin (amoxicillin-clavulanate) for community-acquired pneumonia is 90 mg/kg/day in 2 divided doses, with a maximum dose of 4000 mg/day 1.
- For children, the dose can be given as amoxicillin component, 90 mg/kg/day in 2 doses 1.
- For adults, the typical dose is 875mg/125mg orally every 12 hours or 500mg/125mg orally every 8 hours for 7-10 days 1. However, for more severe cases, the dose can be increased to 1000mg/62.5mg orally every 12 hours. It's essential to note that the dose and duration of treatment may vary depending on the severity of the infection, patient's age, weight, and renal function, as well as local antimicrobial resistance patterns 1.
Important Considerations
- Local antimicrobial resistance patterns should be considered when selecting a treatment regimen 1.
- Patient's age, weight, and renal function should also be taken into account when determining the dose and duration of treatment 1.
- Severe cases may require higher doses or alternative treatments, such as ceftriaxone or cefotaxime 1.
From the FDA Drug Label
For more severe infections and infections of the respiratory tract, the dose should be one 875 mg/125 mg amoxicillin and clavulanate potassium tablet every 12 hours or one 500 mg/125 mg amoxicillin and clavulanate potassium tablet every 8 hours. The recommended dose of Augmentin (amoxicillin-clavulanate) for community-acquired pneumonia is:
- 875 mg/125 mg every 12 hours
- 500 mg/125 mg every 8 hours 2
From the Research
Recommended Dose of Augmentin for Community-Acquired Pneumonia
The recommended dose of Augmentin (amoxicillin-clavulanate) for community-acquired pneumonia is as follows:
- For adults, the dose is 500/125 mg TID or 875/125 mg BID for 7 days 3
- For children, the dose is 90/6.4 mg/kg/day in two divided doses (Augmentin ES-600) 4, 5
- A high-dose formulation of amoxicillin/clavulanate 2000/125 mg twice daily (available as Augmentin XR) has been developed for use in adult respiratory tract infection due to drug-resistant pathogens, such as S. pneumoniae with reduced susceptibility to penicillin 4
Factors Influencing Dose Selection
The selection of dose depends on various factors, including:
- Patient age and weight
- Presence of co-morbidities
- Severity of the infection
- Local susceptibility patterns of S. pneumoniae 3, 5
- Risk of antimicrobial resistance 4, 5
Duration of Therapy
The duration of therapy for community-acquired pneumonia is typically 7 days 3, 6